Because of the in part opposite effects of AA on PBLs from MCAD patients and the high range of dispersion of the AA-triggered PGD2 values, AA-triggered PGD2 release seemed not to be a sufficiently decisive endpoint for diagnostically differentiating MCAD patients from healthy controls. The gene discussed is PTGDS; the disease is medium chain acyl-CoA dehydrogenase deficiency.